LOGIN  |  REGISTER
Assertio

Certara to Participate in Upcoming Investor Conferences

May 03, 2022 | Last Trade: US$10.71 0.16 1.52

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:

  • Bank of America 2022 Healthcare Conference
    Date and Time: Tuesday, May 10 at 3:00 p.m. ET
  • Citi’s Biopharma Virtual Co-Panel Day
    Date and Time: Wednesday, May 18 at 10:00 a.m. ET
  • Jefferies Healthcare Conference
    Date and Time: Wednesday, June 8 – Friday, June 10
    Details to be posted to the Company’s IR website
  • William Blair 42nd Annual Growth Stock Conference
    Date and Time: Thursday, June 9 at 10:20 a.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB